Business
Moderna’s stock has surged 488% in 2020: Is it a buy for 2021?
This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.
This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.
All eyes were on the biotech Moderna (NASDAQ: MRNA) in 2020. It wasn’t quite a popular name in the pharmaceutical space, as it has no approved products on the market yet. But its sudden entry in the COVID-19 vaccine competition grabbed a lot of attention, and it became the second company to win approval in a race with dozens of players. No wonder its stock has surged 488% so far this year, while the S&P 500 has gained 16%.
On Dec. 11, Pfizer (NYSE: PFE) and its German biotech partner BioNTech (NASDAQ: BNTX) became the…
-
Noosa News23 hours agoDrivers call out bad manners and most hated acts on Queensland roads
-
Business24 hours agoHow to build a $250,000 passive income portfolio starting from zero
-
Noosa News23 hours agoCoochin Fields developer asked to explain shortfalls in tourist park proposal
-
Business23 hours agoGuess who just bought $5 million worth of Domino’s Pizza shares?